Segment Wealth Management LLC Purchases 654 Shares of Zoetis Inc. (NYSE:ZTS)

Segment Wealth Management LLC increased its holdings in Zoetis Inc. (NYSE:ZTS) by 0.9% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 75,320 shares of the company’s stock after buying an additional 654 shares during the period. Segment Wealth Management LLC’s holdings in Zoetis were worth $12,272,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ZTS. Cherry Creek Investment Advisors Inc. raised its holdings in shares of Zoetis by 2.0% in the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock valued at $590,000 after acquiring an additional 58 shares in the last quarter. Grove Bank & Trust raised its stake in Zoetis by 0.5% in the third quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock valued at $2,298,000 after purchasing an additional 61 shares in the last quarter. Hancock Whitney Corp lifted its position in Zoetis by 0.3% during the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after purchasing an additional 61 shares during the last quarter. Strategy Asset Managers LLC grew its stake in Zoetis by 3.5% in the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after buying an additional 62 shares in the last quarter. Finally, Procyon Advisors LLC increased its holdings in shares of Zoetis by 1.4% in the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after buying an additional 63 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $166.01 on Tuesday. The company has a market capitalization of $74.90 billion, a P/E ratio of 31.20, a PEG ratio of 2.55 and a beta of 0.89. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a 50 day moving average price of $170.93 and a two-hundred day moving average price of $180.01.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.36 EPS. Analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This is a boost from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ZTS shares. UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. JPMorgan Chase & Co. increased their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Leerink Partners initiated coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average target price of $211.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.